BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34587961)

  • 1. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
    Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
    BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
    Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Rørth M; Ejlertsen B; Lash TL; Ahern TP; Sørensen HT; Cronin-Fenton D
    Breast Cancer Res Treat; 2022 Jul; 194(2):353-363. PubMed ID: 35501422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
    Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
    BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
    Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
    Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Cronin-Fenton D; Kjærsgaard A; Nørgaard M; Amelio J; Liede A; Hernandez RK; Sørensen HT
    Breast Cancer Res Treat; 2018 Jan; 167(2):517-528. PubMed ID: 28948396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
    Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
    Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study.
    Praestegaard C; Kjaer SK; Andersson M; Steding-Jensen M; Frederiksen K; Mellemkjaer L
    Breast Cancer; 2016 Nov; 23(6):908-916. PubMed ID: 26660140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study.
    Cronin-Fenton DP; Kjærsgaard A; Ahern TP; Mele M; Ewertz M; Hamilton-Dutoit S; Christiansen PM; Ejlertsen B; Sørensen HT; Lash TL; Silliman RA
    Acta Oncol; 2017 Sep; 56(9):1155-1160. PubMed ID: 28585885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
    Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
    Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site.
    Lagergren J; Andersson G; Talbäck M; Drefahl S; Bihagen E; Härkönen J; Feychting M; Ljung R
    Cancer; 2016 Jan; 122(2):207-12. PubMed ID: 26447737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study.
    Falstie-Jensen AM; Kjærsgaard A; Lorenzen EL; Jensen JD; Reinertsen KV; Dekkers OM; Ewertz M; Cronin-Fenton DP
    Breast Cancer Res; 2019 Mar; 21(1):44. PubMed ID: 30902106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
    Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.